Cargando…
Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up
INTRODUCTION: Alendronate is the most popular bisphosphonate used to prevent fragility fracture of postmenopausal osteoporosis. There is common belief among physicians that Alendronates are very safe without many side effects and they continue it for long time. Recent papers have shown that, some pa...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Indian Orthopaedic Research Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701117/ https://www.ncbi.nlm.nih.gov/pubmed/27298837 |
_version_ | 1782408428334874624 |
---|---|
author | Jain, Sumit Kumar Roy, Shuvendu Prosad Nagi, Onkar Nath |
author_facet | Jain, Sumit Kumar Roy, Shuvendu Prosad Nagi, Onkar Nath |
author_sort | Jain, Sumit Kumar |
collection | PubMed |
description | INTRODUCTION: Alendronate is the most popular bisphosphonate used to prevent fragility fracture of postmenopausal osteoporosis. There is common belief among physicians that Alendronates are very safe without many side effects and they continue it for long time. Recent papers have shown that, some patients who are on this drug from a long period suffered a rare type of fracture. We are reporting a similar type of case for the first time from Indian subcontinent but with a different associated medical condition. CASE PRESENTATION: A 75 years old female presented with spontaneous fracture of right femur diaphysis. She was on Alendronate for past six years. Her bone metabolic picture also revealed vitamin D insufficiency and secondary hyperparathyroidism. CONCLUSION: Alendronate induced atypical fracture in association with secondary hyperparathyroidism is an unusual presentation which has not been reported in any of the case reports till date as per our knowledge. This type of presentation may need future investigation both for disease pathophysiology and future outcome in this type of fracture treatment. Treatment of osteoporosis with antiresoptive agent, alendronate; warrants careful follow-up |
format | Online Article Text |
id | pubmed-4701117 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Indian Orthopaedic Research Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-47011172016-06-13 Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up Jain, Sumit Kumar Roy, Shuvendu Prosad Nagi, Onkar Nath J Orthop Case Reports Trauma INTRODUCTION: Alendronate is the most popular bisphosphonate used to prevent fragility fracture of postmenopausal osteoporosis. There is common belief among physicians that Alendronates are very safe without many side effects and they continue it for long time. Recent papers have shown that, some patients who are on this drug from a long period suffered a rare type of fracture. We are reporting a similar type of case for the first time from Indian subcontinent but with a different associated medical condition. CASE PRESENTATION: A 75 years old female presented with spontaneous fracture of right femur diaphysis. She was on Alendronate for past six years. Her bone metabolic picture also revealed vitamin D insufficiency and secondary hyperparathyroidism. CONCLUSION: Alendronate induced atypical fracture in association with secondary hyperparathyroidism is an unusual presentation which has not been reported in any of the case reports till date as per our knowledge. This type of presentation may need future investigation both for disease pathophysiology and future outcome in this type of fracture treatment. Treatment of osteoporosis with antiresoptive agent, alendronate; warrants careful follow-up Indian Orthopaedic Research Group 2011 /pmc/articles/PMC4701117/ /pubmed/27298837 Text en Copyright: © Indian Orthopaedic Research Group http://creativecommons.org/licenses/by-nc-sa/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Trauma Jain, Sumit Kumar Roy, Shuvendu Prosad Nagi, Onkar Nath Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up |
title | Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up |
title_full | Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up |
title_fullStr | Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up |
title_full_unstemmed | Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up |
title_short | Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up |
title_sort | treatment of osteoporosis with antiresoptive agent, alendronate - warrants careful follow-up |
topic | Trauma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701117/ https://www.ncbi.nlm.nih.gov/pubmed/27298837 |
work_keys_str_mv | AT jainsumitkumar treatmentofosteoporosiswithantiresoptiveagentalendronatewarrantscarefulfollowup AT royshuvenduprosad treatmentofosteoporosiswithantiresoptiveagentalendronatewarrantscarefulfollowup AT nagionkarnath treatmentofosteoporosiswithantiresoptiveagentalendronatewarrantscarefulfollowup |